Effects of Anti-TNFα Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn’s Disease

Table 1

Baseline characteristics.

Patient number	Gender	Immunosuppressant	Behavior	Location	Smoking status	CDAI	HBI	SES-CD	CRP	Fecal calprotectin
1	M	Yes	Stricturing	Ileal	No	301	6	8	8	576
2	F	Yes	Penetrating	Colonic	No	266	10	8	0.6	148
3	M	No	Nonstricturing, nonpenetrating	Colonic	No	153	4	16	3.2	1215
4	F	No	Nonstricturing, nonpenetrating	Colonic	No	299	8	11	51.7	>3600
5	M	Yes	Stricturing	Ileocolonic	No	292	10	17	0.8	405
6	M	Yes	Nonstricturing, nonpenetrating	Ileocolonic	Yes	315	10	7	9.8	941
7	M	No	Nonstricturing, nonpenetrating	Colonic	No	232	12	15	1.4	Missing
8	F	Yes	Nonstricturing, nonpenetrating	Colonic	No	179	7	18	3.8	342
9	F	Yes	Nonstricturing, nonpenetrating	Colonic	No	251	12	14	12.0	495
10	F	Yes	Nonstricturing, nonpenetrating	Colonic	No	296	10	10	5.7	178
11	M	Yes	Nonstricturing, nonpenetrating	Colonic	No	238	11	15	0.9	211
12	M	No	Stricturing	Ileocolonic	No	295	9	15	36.5	>3600

CRP: C-reactive protein in mg/L, reference < 8 mg/L; Fecal calprotectin, reference < 50 mg/kg.